Executive SummaryPharmacopeia's deal with Schering-Plough is one of the very few rich alliances in a technology area in which only Affymax has proven that it can attract significant big-company funding. Selectide's acquisition by Marion Merrell Dow raises questions about how much this technology can be partnered: many potentialpartners believe they can develop the technology on their own, or if they can't, want to use the start-up's libraries against all of their targets--a virtual acquisition. Real acquisition might be the best option.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.